Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Incyte

The Food and Drug Administration will expedite its review of capmatinib.

Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA

Abbott Labs

AstraZeneca

Bristol-Myers

Eli Lilly

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings.

5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher

LONDON and REDWOOD CITY, Calif., Feb.  10, 2020  (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million convertible equity financing with Novartis Pharma (AG) (“Novartis”) and concurrently entered into a Securities Purchase Agreement to issue up to $28 million of the Company’s ordinary shares exchangeable for American Depositary Shares (“ADSs”), including a $3 million initial purchase, with Aspire Capital Fund, LLC (“Aspire Capital”), a Chicago-based institutional investor. Proceeds from these transactions are intended to be used by Mereo for general corporate purposes, including clinical trial activity and working capital.

Mereo BioPharma Enters into a $5 Million Convertible Equity Financing with Novartis and Announces a Securities Purchase Agreement with Aspire Capital Fund, LLC for up to $28 Million

Biogen

Vertex Pharmaceuticals

We examine three biotech companies' past performances and future outlooks.

3 Biotech Companies Analyzed

Bertrand Bodson, chief digital officer of Novartis, in conversation with Stephanie Mehta at the 2020 World Economic Forum in Davos, Switzerland. 

		 
			 
		
			if(typeof(jQuery)=="function"){(function($){$.fn.fitVids=function(){}})(jQuery)};
				jwplayer('jwplayer_pi0Enztb_G2hQKLvX_div').setup(
				{"playlist":"https:\/\/content.jwplatform.com\/feeds\/pi0Enztb.json","ph":2}
			);
		
	
Bertrand Bodson, chief digital officer of Novartis, in conversation with Stephanie Mehta at the 2020 World Economic Forum in Davos, Switzerland.

Video: Novartis’s chief digital officer on how the company is becoming un-bossed

Mylan

Teva Pharmaceutical

Regulators are trying their best to help encourage competition, particularly in the biosimilars market.

The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers

Novartis Revenue Jumps, And Other News: The Good, Bad And Ugly Of Biopharma

UnitedHealth Group

Welltower

An exciting new discovery holds the potential to completely disrupt the healthcare industry as we know it.

A Cure for Cancer Might Be on the Way -- and It Could Turn Healthcare Investing Upside Down

Despite missing some analyst targets, the pharmaceutical giant reported reasonable results overall.

Novartis Reports Q4 2019 Financial Results, Zolgensma Sales Fall Short

Novartis AG (NVS) CEO Vasant Narasimhan on Q4 2019 Results - Earnings Call Transcript

Novartis stock edged higher into a buy zone Wednesday after the Swiss pharmaceutical company topped fourth-quarter earnings views, though sales were slightly lighter than analysts expected.
The post Novartis Edges Higher Into Buy Zone Even As Generic Drugs Struggle appeared first on Investor's Business Daily.

Novartis Edges Higher Into Buy Zone Even As Generic Drugs Struggle

Novartis (NVS) reports disappointing results for the fourth quarter but provides an encouraging outlook for 2020.

Novartis (NVS) Earnings and Revenues Miss Estimates in Q4

Novartis earnings edged past Q4 views early Wednesday. Shares of the Swiss drug giant rose in its buy zone after Tuesday's bullish rebound.

Novartis Earnings Narrowly Top; Drug Giant Rises In Buy Zone

The chief executive of Novartis believes it will take at least 12 months to find a new vaccine to treat the coronavirus.

Swiss pharmaceutical giant warns finding a coronavirus vaccine will take 'over a year'

Roche Holding AG

Sarepta Therapeutics

The number of gene therapy candidates is expected to skyrocket in the near future.

FDA Expects Explosion in Gene Therapy Treatments, Updates Review Policy

Humana

Walgreens

The sector is a safe bet for long-term growth, but which health-care stocks stand to gain the most? Here are three picks to consider today.

3 Great Healthcare Stocks to Buy Right Now

The company recently received some great news about its cholesterol drug.

Will This Send Novartis Stock Soaring?

Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.

Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe

Is Novartis AG (NVS) a great pick from the value investor's perspective right now? Read on to know more.

Is Novartis AG (NVS) A Suitable Pick for Value Investors?

New treatments for breast cancer, multiple sclerosis, and others make the drugmaker's stock a more compelling buy in 2020.

Novartis Starts 2020 a Step Ahead of Other Big Pharmas with the Most Newly Approved Drugs

AbbVie

The results should help the upstart drug to compete with Cosentyx.

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

Cholesterol-lowering inclisiran could be available in the country as early as 2021.

Novartis' Heart Drug Gets Accelerated Review in Britain for High-Risk Patients

The Swiss drugmaker will provide the drug to patients with Atherosclerosis, a heart disease in which plaque builds up inside arteries and can lead to issues, including heart attack or death.

Novartis strikes deal with UK to provide cholesterol drug to high-risk patients

Allergan

Merck

Novartis AG, Merck & Co Inc and Allergan Plc were among companies that raised U.S. prices on more than 100 prescription medicines on Friday, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors.

News for Novartis Stock (NVS)